171 related articles for article (PubMed ID: 34647426)
41. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
42. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
43. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
[TBL] [Abstract][Full Text] [Related]
44. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.
Sehgal K; Peters MLB; VanderLaan PA; Rangachari D; Kobayashi SS; Costa DB
J Thorac Oncol; 2019 Jan; 14(1):e1-e3. PubMed ID: 29981924
[No Abstract] [Full Text] [Related]
45. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
46. Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC.
Hoy SM
Drugs; 2021 Feb; 81(2):267-275. PubMed ID: 33528789
[TBL] [Abstract][Full Text] [Related]
47. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
48. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
Tomasini P; Egea J; Souquet-Bressand M; Greillier L; Barlesi F
Ther Adv Respir Dis; 2019; 13():1753466619831906. PubMed ID: 30786826
[TBL] [Abstract][Full Text] [Related]
49. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D
Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334
[TBL] [Abstract][Full Text] [Related]
50. Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/cisT790M/cisC797S NSCLC: A Case Report.
Lee BJ; Lim CK; Chang HT; Zhang JH
Am J Case Rep; 2022 Sep; 23():e937209. PubMed ID: 36146910
[TBL] [Abstract][Full Text] [Related]
51. Brigatinib: First Global Approval.
Markham A
Drugs; 2017 Jul; 77(10):1131-1135. PubMed ID: 28597393
[TBL] [Abstract][Full Text] [Related]
52. Intracranial Response of ALK
Urbanska EM; Santoni-Rugiu E; Melchior LC; Carlsen JF; Sørensen JB
Clin Lung Cancer; 2021 Jul; 22(4):e528-e532. PubMed ID: 32651064
[No Abstract] [Full Text] [Related]
53. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
[TBL] [Abstract][Full Text] [Related]
54. Treatment of brain metastases in ALK-positive non-small cell lung cancer.
Ceddia S; Codacci-Pisanelli G
Crit Rev Oncol Hematol; 2021 Sep; 165():103400. PubMed ID: 34147645
[TBL] [Abstract][Full Text] [Related]
55. Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
Pellerino A; Buffoni L; Rudà R; Soffietti R
Neurology; 2019 Jul; 93(5):217-219. PubMed ID: 31248938
[No Abstract] [Full Text] [Related]
56. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Sakamoto MR; Honce JM; Lindquist DL; Camidge DR
Clin Lung Cancer; 2019 Mar; 20(2):e133-e136. PubMed ID: 30578110
[No Abstract] [Full Text] [Related]
57. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
58. Brigatinib Effective in ALK+ NSCLC.
Cancer Discov; 2017 Jan; 7(1):4-5. PubMed ID: 27899405
[TBL] [Abstract][Full Text] [Related]
59. Optimal management of ALK-positive NSCLC progressing on crizotinib.
Metro G; Tazza M; Matocci R; Chiari R; Crinò L
Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
[TBL] [Abstract][Full Text] [Related]
60. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
